New Haven, CT (PRWEB) August 29, 2017
As part of a transformative effort to bring precision medicine to the bedside and the exam room, Yale New Haven Health System (YNHHS) of New Haven, Connecticut is adding ActX Genomic Decision Support to its Electronic Health Record, Epic.
The ActX platform includes evidence based clinical decision support content covering drug-genome interactions, hereditary genetic risks and carrier status. YNHHS will begin by integrating the ActX Genomic Decision Support for pharmacogenomics with the electronic health record used through its five hospitals and over 400 ambulatory sites, including the 1541 bed Academic Medical Center – Yale New Haven Hospital. This integration brings genomics to the bedside by leveraging the ActX service to enable real-time checking of each prescription against the patient’s genetic profile. Within their normal Epic order workflow, prescribers will receive alerts about potential adverse reactions, drug efficacy, or dosing based on the patient’s genetic findings. An embedded Genomic Profile for each patient will also be available within Epic.
The initial focus for real-time pharmacogenomics will be within behavioral health, cardiology, infectious disease, and pediatrics departments. By implementing the ActX genomic decision support service, YNHH will use the latest genetic knowledge to help its physicians choose the best medications for patients by avoiding adverse reactions and ineffective medications.
“Yale has been a pioneer in genomics and its applications for clinical use. Genomic health, where we can deliver actionable interpretations directly to clinical providers, is key to Yale New Haven Health’s vision for precision medicine. We plan to provide this valuable information directly to our physicians across the health system so we can continue to deliver the best care possible to our patients,” notes Allen Hsiao, Chief Medical Information Officer for Yale New Haven Health and Yale School of Medicine.
“We are proud to partner with Yale New Haven Health System to bring genomic decision support and precision medicine to such a prestigious academic hospital,” said Dr. Andrew Ury, CEO of ActX. “The ActX Platform for Epic will help make actionable genomics practical for Yale New Haven physicians and their patients."
YNHHS’s implementation of ActX within Epic marks a big step toward making personalized medicine the norm for its patients. To learn more about ActX, visit http://www.actx.com.
ActX helps physicians make better decisions about medical treatment, using patients’ genetic information. Integrated into the physician’s software tools and workflow, ActX analyzes the patient’s genetic information in real time and alerts physicians about drug-genome interactions, actionable hereditary risks and carrier status. For more information, visit http://www.actx.com, email info(at)actx(dot)com or call (888) 998-2289.
About Yale New Haven Health
A leading integrated delivery system with five hospitals and a Physician management group comprising the largest health system in Connecticut. Yale New Haven Hospital (YNHH) is a non-profit, 1,541-bed tertiary academic medical center receiving national and international referrals. Yale New Haven Hospital includes Smilow Cancer Hospital, Yale New Haven Children's Hospital and Yale New Haven Psychiatric Hospital. Bridgeport Hospital has 383 licensed beds plus 42 beds licensed under Yale New Haven Children’s Hospital. Greenwich Hospital is a 206-bed regional hospital, serving Fairfield County, Connecticut and Westchester County, New York. All three hospitals are a major academic affiliate of Yale University School of Medicine. Laurence + Memorial Hospital is a 280 bed regional hospital located in the eastern part of CT, Westerly Hospital is a 60 bed hospital serving the western shoreline of RI, Northeast Medical Group (NEMG), is a physician group affiliated with YNHHS. NEMG includes community physicians in Fairfield and New Haven counties in Connecticut, as well as Westchester County, NY